


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:22Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405300" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405300</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocr Pathol</journal-id><journal-id journal-id-type="iso-abbrev">Endocr Pathol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Endocrine Pathology</journal-title></journal-title-group><issn pub-type="ppub">1046-3976</issn><issn pub-type="epub">1559-0097</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405300</article-id><article-id pub-id-type="pmcid-ver">PMC12405300.1</article-id><article-id pub-id-type="pmcaid">12405300</article-id><article-id pub-id-type="pmcaiid">12405300</article-id><article-id pub-id-type="pmid">40892116</article-id><article-id pub-id-type="doi">10.1007/s12022-025-09874-z</article-id><article-id pub-id-type="publisher-id">9874</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>DICER1-Related Pediatric Thyroid Neoplasm with Follicular and Morular Growth: A Tumor that Did Not Read the Textbook</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cameselle-Teijeiro</surname><given-names initials="JM">Jos&#233; Manuel</given-names></name><address><email>josemanuel.cameselle@usc.es</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verma</surname><given-names initials="S">Sangeeta</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Penn</surname><given-names initials="A">Anthony</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sethuraman</surname><given-names initials="C">Chitra</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amendoeira</surname><given-names initials="I">Isabel</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garrido-Gil</surname><given-names initials="P">Pablo</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Labandeira-Garc&#237;a</surname><given-names initials="JL">Jos&#233; Lu&#237;s</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sobrino</surname><given-names initials="B">Beatriz</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ru&#237;z-Ponte</surname><given-names initials="C">Clara</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sobrinho-Sim&#245;es</surname><given-names initials="M">Manuel</given-names></name><address><email>ssimoes@ipatimup.pt</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/030eybx10</institution-id><institution-id institution-id-type="GRID">grid.11794.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 0645</institution-id><institution>Department of Pathology, </institution><institution>Clinical University Hospital of Santiago de Compostela, Galician Healthcare Service (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Medical Faculty, University of Santiago de Compostela, </institution></institution-wrap>Traves&#237;a Choupana s/n, Santiago de Compostela, 15706 Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v9efr22</institution-id><institution-id institution-id-type="GRID">grid.412917.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0430 9259</institution-id><institution>Department of Histopathology, </institution><institution>The Christie NHS Foundation Trust, </institution></institution-wrap>Manchester, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052vjje65</institution-id><institution-id institution-id-type="GRID">grid.415910.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0235 2382</institution-id><institution>Department of Paediatric Oncology, </institution><institution>Royal Manchester Children&#8217;s Hospital, </institution></institution-wrap>Manchester, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00he80998</institution-id><institution-id institution-id-type="GRID">grid.498924.a</institution-id><institution>Department of Paediatric Histopathology, </institution><institution>Manchester University NHS Foundation Trust, </institution></institution-wrap>Oxford Road, Manchester, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>Department of Pathology, ULS S&#227;o Jo&#227;o, Institute of Molecular Pathology and Immunology (IPATIMUP), i3S-Institute for Research &amp; Innovation in Health, </institution><institution>University of Porto, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/030eybx10</institution-id><institution-id institution-id-type="GRID">grid.11794.3a</institution-id><institution-id institution-id-type="ISNI">0000000109410645</institution-id><institution>Research Center for Molecular Medicine and Chronic Diseases (CiMUS), Networking Research Center on Neurodegenerative Diseases (CIBERNED), </institution><institution>Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, </institution></institution-wrap>Santiago de Compostela, Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n7xcf53</institution-id><institution-id institution-id-type="GRID">grid.488911.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0408 4897</institution-id><institution>Fundaci&#243;n P&#250;blica Galega de Medicina Xen&#243;mica, Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Raras (CIBERER), </institution><institution>Servicio Galego de Sa&#250;de (SERGAS), Instituto de Investigaci&#243;n Sanitaria de Santiago de Compostela (IDIS), Grupo de Medicina Xen&#243;mica-Universidade de Santiago de Compostela, </institution></institution-wrap>Santiago de Compostela, Spain </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>Department of Pathology, Medical Faculty, Institute of Molecular Pathology and Immunology (IPATIMUP), i3S-Institute for Research &amp; Innovation in Health, </institution><institution>University of Porto, </institution></institution-wrap>Porto, 4200-135 Portugal </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>36</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>31</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12022_2025_Article_9874.pdf"/><abstract id="Abs1"><p id="Par1">Thyroid lesions associated with <italic toggle="yes">DICER1</italic> syndrome include multifocal hyperplastic and benign neoplastic proliferations (follicular nodular disease) with characteristic macrofollicular and/or intrafollicular centripetal papillary growth patterns, frequently associated with atrophic and involutional changes. There are also well-differentiated thyroid carcinomas showing intermediate-type nuclei, sometimes combining high-grade areas (tumor-in-tumor pattern) and poorly differentiated carcinomas. Here, for the first time, we describe an encapsulated follicular cell thyroid tumor showing a mixed follicular and morular growth pattern, which presented in an 11-year-old girl with follicular nodular disease and a constitutional (germline) <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) pathogenic variant. The tumoral follicular component showed colloid and tumor cells with round nuclei, frequent chromatin clearing, and overlapping without grooves or pseudoinclusions (intermediate-type nuclei). There were scattered mitotic figures, but no tumor necrosis, infiltration, or vascular invasion. The morular structures lacked keratinization. The follicular areas were positive for TTF1/NKX2, PAX8, thyroglobulin, thyroperoxidase, keratin clones CKAE1/AE3 and 34bE12, CK19, and vimentin, whereas the morular component was positive for CKAE1/AE3, CK19, CD10, and CDX2. Aberrant (nuclear and cytoplasmic) immunolabeling pattern for &#946;-catenin was limited to the morular structures. The Ki67 proliferation index was 21% in the follicular component and less than 1% in the morulae. In addition to the constitutional <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) variant, the somatic <italic toggle="yes">DICER1</italic> p.(Asp1910Tyr) oncogenic variant and the somatic <italic toggle="yes">CTNNB1</italic> p.(Thr41Ala) oncogenic variant were also identified in this tumor. This &#8220;DICER1-related pediatric thyroid neoplasm with follicular and morular growth&#8221; expands the spectrum of <italic toggle="yes">DICER1</italic>-associated thyroid lesions. Indirectly, the absence of follicular markers only in the areas with WNT/&#946;-catenin pathway activation (morular structures) in this neoplasm could explain the absence of follicular differentiation in cribriform morular thyroid carcinoma. The additional study of one of the accompanying thyroid nodules (follicular nodular disease) confirmed the constitutional <italic toggle="yes">DICER1</italic> variant, along with <italic toggle="yes">DICER1</italic> p.(Asp1709Gly) and p.(Asp1810Val) variants.
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Thyroid</kwd><kwd><italic toggle="yes">DICER1</italic></kwd><kwd><italic toggle="yes">CTNNB1</italic></kwd><kwd>Pediatric thyroid cancer</kwd><kwd>Thyroid tumor</kwd><kwd>Morular structures</kwd><kwd>&#946;-Catenin</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>PI23/00722</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Universidade de Santiago de Compostela</institution></funding-source></award-group><open-access><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2"><italic toggle="yes">DICER1</italic> syndrome is associated with a wide range of characteristic tumors and dysplastic disorders caused by heterozygous germline pathogenic variants in the <italic toggle="yes">DICER1</italic> gene [<xref ref-type="bibr" rid="CR1">1</xref>]. <italic toggle="yes">DICER1</italic>, located on chromosome 14q32, functions canonically as an RNase III endoribonuclease essential for microRNA biogenesis. RNase IIIb-mutated <italic toggle="yes">DICER1</italic> exhibits abnormal 5p microRNA processing, resulting in an altered 5p:3p microRNA ratio, which, together with simultaneous dysregulation of gene expression, underlies tumor development [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Within the histological spectrum of <italic toggle="yes">DICER1</italic>-associated tumors, thyroid follicular nodular disease (TFND) is one of the most prevalent lesions [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition to TFND, differentiated thyroid carcinoma [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and poorly differentiated thyroid carcinoma [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] have been described in childhood or adolescence related to germline <italic toggle="yes">DICER1</italic> mutations, while thyroblastoma is more common in adults and is typically associated with somatic mutations in <italic toggle="yes">DICER1</italic> [<xref ref-type="bibr" rid="CR8">8</xref>]. In the context of <italic toggle="yes">DICER1</italic> syndrome, thyroid involvement often also includes a series of histopathological features such as follicular adenomas with macrofollicular growth pattern and papillary infoldings [<xref ref-type="bibr" rid="CR9">9</xref>], atrophic and/or involutional changes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], and the presence of intermediate nuclei, which may alert the pathologist to the possibility of <italic toggle="yes">DICER1</italic> syndrome [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par3">Here, we describe, for the first time, an encapsulated follicular cell thyroid tumor showing a mixed follicular and morular growth pattern, presented in a girl with a germline <italic toggle="yes">DICER1</italic> gene mutation. This tumor broadens the spectrum of <italic toggle="yes">DICER1</italic>-associated thyroid tumors. The morphological, immunohistochemical, and molecular characteristics of this DICER1-related pediatric thyroid neoplasm with follicular and morular growth also provide additional information on the pathogenesis of both pediatric thyroid tumors and cribriform morular thyroid carcinoma [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec2"><title>Material and Methods</title><sec id="Sec3"><title>Case History
</title><p id="Par4">An 11-year-old girl underwent a right lobectomy to complete a thyroidectomy for multiple thyroid nodules. The patient had been identified as having <italic toggle="yes">DICER1</italic> syndrome after genetic screening following the diagnosis of the syndrome in her older sister who was treated for pineoblastoma. After follow-up ultrasound studies, a left hemithyroidectomy had been performed, leading to the pathological diagnosis of &#8220;Dominant hyperplastic nodule of a syndromic situation that may be associated with <italic toggle="yes">DICER1</italic> mutation.&#8221; Nine months after the first surgery, the thyroidectomy was completed due to several enlarged nodules in the remaining thyroid lobe. Based on the lack of invasiveness of the tumor, radioactive iodine was not administered. The patient receives hormone replacement treatment, is being monitored periodically (including serum thyroglobulin levels), and is doing well with no evidence of other alterations, 17&#160;months after the second surgical intervention.</p></sec><sec id="Sec4"><title>Pathological and Immunohistochemical Analysis</title><p id="Par5">The right hemithyroidectomy specimen was fixed in neutral, phosphate-buffered, 10% formalin and included in paraffin blocks. Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with hematoxylin&#8211;eosin; immunohistochemical studies were also performed on 4-&#181;m-thick paraffin sections using a peroxidase-conjugated-labeled dextran polymer (Dako EnVision Peroxidase/DAB; Dako, Glostrup, Denmark), with 3,3&#8242;-diaminobenzidine as the chromogen, and using a series of primary antibodies whose main characteristics are described in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Immunohistochemical characteristics of the DICER1-related pediatric thyroid neoplasm with follicular and morular growth</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Antibodies</th><th align="left" rowspan="2" colspan="1">Clone</th><th align="left" rowspan="2" colspan="1">Dilution</th><th align="left" rowspan="2" colspan="1">Antigen retrieval</th><th align="left" rowspan="2" colspan="1">Manufacturer</th><th align="left" colspan="2" rowspan="1">Tumor cells</th></tr><tr><th align="left" colspan="1" rowspan="1">Follicular component</th><th align="left" colspan="1" rowspan="1">Morular structures</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TG</td><td align="left" colspan="1" rowspan="1">Polyclonal</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 6</td><td align="left" colspan="1" rowspan="1">Dako, Glostrup, Denmark</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">TPO</td><td align="left" colspan="1" rowspan="1">MoAb47</td><td align="left" colspan="1" rowspan="1">1/50</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">CT</td><td align="left" colspan="1" rowspan="1">Polyclonal</td><td align="left" colspan="1" rowspan="1">1/400</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">TTF1</td><td align="left" colspan="1" rowspan="1">SPT24</td><td align="left" colspan="1" rowspan="1">1/100</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Gennova, Sevilla, Spain</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">-/+&#8201;*</td></tr><tr><td align="left" colspan="1" rowspan="1">PAX8</td><td align="left" colspan="1" rowspan="1">SP348</td><td align="left" colspan="1" rowspan="1">1/100</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Gennova</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">-/+&#8201;*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-catenin</td><td align="left" colspan="1" rowspan="1">&#946;-Catenin-1</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">m</td><td align="left" colspan="1" rowspan="1">mcn</td></tr><tr><td align="left" colspan="1" rowspan="1">Keratins</td><td align="left" colspan="1" rowspan="1">CKAE1/AE3</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td></tr><tr><td align="left" colspan="1" rowspan="1">Keratins</td><td align="left" colspan="1" rowspan="1">CK19</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td></tr><tr><td align="left" colspan="1" rowspan="1">Keratins</td><td align="left" colspan="1" rowspan="1">34bE12</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Vimentin</td><td align="left" colspan="1" rowspan="1">V9</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">CD5</td><td align="left" colspan="1" rowspan="1">4C7</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">CD10</td><td align="left" colspan="1" rowspan="1">DAK-CD10</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-*</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;&#8201;+&#8201;</td></tr><tr><td align="left" colspan="1" rowspan="1">CDX2</td><td align="left" colspan="1" rowspan="1">DAK-CDX2</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#8201;+&#8201;</td></tr><tr><td align="left" colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1">EP1/IR044IVD</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">PR</td><td align="left" colspan="1" rowspan="1">636/IR068</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">p40</td><td align="left" colspan="1" rowspan="1">DAK-p40</td><td align="left" colspan="1" rowspan="1">Ready to use</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">SALL4</td><td align="left" colspan="1" rowspan="1">IHC659</td><td align="left" colspan="1" rowspan="1">1:50</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">GenomeMe, BC, Canada</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Ki67</td><td align="left" colspan="1" rowspan="1">MIB1</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">pH 9</td><td align="left" colspan="1" rowspan="1">Dako</td><td align="left" colspan="1" rowspan="1">21%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;1%</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">TG</italic>, thyroglobulin; <italic toggle="yes">TPO</italic>, thyroperoxidase; <italic toggle="yes">CT</italic>, calcitonin; <italic toggle="yes">TTF1/NKX2&#8208;1</italic>, NK2 homeobox 1; <italic toggle="yes">PAX8</italic>, paired box 8; <italic toggle="yes">ER</italic>, estrogen receptors-&#945;; <italic toggle="yes">PR</italic>, progesterone receptors; <italic toggle="yes">m</italic>, membrane positivity; <italic toggle="yes">mcn</italic>, membrane and cytoplasm positivity with strong nuclear positivity. *Positivity in a few isolated cells</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Laser Capture Microdissection</title><p id="Par6">Laser capture microdissection (LCM) was used to isolate pools of thyroid cells from (1) main nodule, including both follicular and morular pattern areas, (2) morular structures, (3) one of the macrofollicular thyroid adenomas, and (4) &#8220;normal&#8221; thyroid tissue, from FFPE tissue sections stained with hematoxylin. LCM was performed using a PALM MicroBeam system (Zeiss, Jena, Germany), equipped with an inverted microscope (Axio Observer.Z1), a motorized stage, and an ultraviolet laser, and controlled by PALM RoboSoftware version 4.2 (Zeiss) (see details in Garrido-Gil et al. [<xref ref-type="bibr" rid="CR15">15</xref>]). The mixed follicular and morular areas of the main nodule and the other cell pools were identified and visualized under bright-field microscopy using a 40&#8201;&#215;&#8201;objective, with the aid of an AxioCam Icc camera (Zeiss). The different cell pools were selected and outlined using the software interface, and subsequently microdissected and catapulted into Zeiss adhesive microtube caps via laser pulses. Captured cell pools were lysed and stored at&#8201;&#8722;&#8201;80 &#176;C until further processing.</p></sec><sec id="Sec6"><title>Genetic Analysis</title><p id="Par7">Whole-exome sequencing (WES) was carried out on DNA extracted from different pools of FFPE tissues obtained by LCM. DNA extraction was undertaken using the QIAamp DNA FFPE Advanced kit (Qiagen, Germany). WES was performed using the KAPA HyperPrep Kit (Roche Sequencing Solutions, Inc.) for library preparation and KAPA HyperExome v2 (Roche) for capturing the region of interest following KAPA HyperCap Workflow manufacturer&#8217;s protocol. Exome libraries were sequenced on the NovaSeq 6000 (Illumina, Inc.) with 2&#8201;&#215;&#8201;100 bp pair-end reads. The sequence reads were aligned to the human reference genome GRCh38 with the Illumina software DRAGEN v4.3.13, with an average coverage greater than 150&#8201;&#215;. To obtain the tumor-exclusive variants, the normal thyroid tissue was used for the normal-tumor paired analyses. The exome analysis was restricted to the <italic toggle="yes">APC</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000038.6">NM_000038.6</ext-link>), <italic toggle="yes">AXIN1</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003502.4">NM_003502.4</ext-link>), <italic toggle="yes">AXIN2</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_004655.4">NM_004655.4</ext-link>), and <italic toggle="yes">CTNNB1</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001904.4">NM_001904.4</ext-link>) genes involved in the canonical WNT/&#946;-catenin pathway, along with <italic toggle="yes">DICER1</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_177438.3">NM_177438.3</ext-link>) and other genes involved in the pathogenesis of follicular thyroid tumors: <italic toggle="yes">BRAF</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_004333.6">NM_004333.6</ext-link>), <italic toggle="yes">NRAS</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002524.5">NM_002524.5</ext-link>), <italic toggle="yes">KRAS</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_033360.4">NM_033360.4</ext-link>), <italic toggle="yes">HRAS</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_176795.5">NM_176795.5</ext-link>), <italic toggle="yes">EIF1AX</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001412.4">NM_001412.4</ext-link>), <italic toggle="yes">PTEN</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000314.8">NM_000314.8</ext-link>), <italic toggle="yes">TERT</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_198253.3">NM_198253.3</ext-link>), <italic toggle="yes">PI3KCA</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006218.4">NM_006218.4</ext-link>), <italic toggle="yes">KMT2C</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_170606.3">NM_170606.3</ext-link>), <italic toggle="yes">KMT2D</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003482.4">NM_003482.4</ext-link>), <italic toggle="yes">CHEK2</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_007194.4">NM_007194.4</ext-link>), <italic toggle="yes">ATM</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000051.4">NM_000051.4</ext-link>), and <italic toggle="yes">TP53</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000546.6">NM_000546.6</ext-link>). Genetic variants were described according to the Human Genome Variation Society (HGVS) (<ext-link ext-link-type="uri" xlink:href="https://varnomen.hgvs.org/">https://varnomen.hgvs.org/</ext-link>), and the classification of pathogenicity was performed according to the standards of pathogenicity of somatic variants in cancer [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Pathological and Immunohistochemical Features</title><p id="Par8">The thyroid lobectomy specimen showed a solid encapsulated dominant nodule measuring 15&#160;mm in diameter and multiple non-encapsulated nodules of up to 9&#160;mm with an adenomatous appearance (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Histologically, the main nodule was well demarcated by a thin band of fibrosis and showed a mixed follicular and morular growth pattern (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Areas with a follicular pattern predominated (approximately 60%), with uniform follicles containing colloid, which were somewhat smaller than the follicles in the non-lesional thyroid. The cells of the follicular component were cuboidal and had round nuclei, with frequent chromatin clearing and overlapping but without grooves or nuclear pseudoinclusions (intermediate-type nuclei) (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). The morular component represented approximately 40% of the tumor cell mass, and these morulae (squamoid whorls) were distributed throughout the tumor, occasionally becoming confluent. These morulae were round or oval, lacked keratinization, and displayed some nuclei with peculiar nuclear clearing of the chromatin (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). There were scattered mitotic figures in the follicular component, but no tumor necrosis, infiltration, or vascular invasion was evident.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>DICER1-related pediatric thyroid neoplasm with follicular and morular growth. Low magnification of a thyroid section showing various nodules (top) and the tumor with follicular and morular growth (bottom). The same constitutional <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) mutation identified in the histologically normal thyroid tissue (right) was also confirmed in one adenomatous nodule and in the tumor with follicular and morular growth (bottom). Additionally, two different <italic toggle="yes">DICER1</italic> p.(Asp1709Gly) and p.(Asp1810Val) mutations were detected in the adenomatous nodule. The tumor with follicular and morular growth showed another different <italic toggle="yes">DICER1</italic> p.(Asp1810Tyr) mutation along with a <italic toggle="yes">CTNNB1</italic> p.(Thr41Ala) mutation</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12022_2025_9874_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>DICER1-related pediatric thyroid neoplasm with follicular and morular growth. The tumor is well-delimited by a thin fibrous capsule (<bold>A</bold>) and composed of a mixed combination of follicles and morular structures (<bold>A</bold>&#8211;<bold>C</bold>). The follicular pattern is predominant, usually containing colloid and lined by cells showing nuclear overlapping and clear chromatin (<bold>B, C</bold>). Morular structures lack keratinization (<bold>C</bold>)</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12022_2025_9874_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>DICER1-related pediatric thyroid neoplasm with follicular and morular growth. In this tumor, the morular structures were scattered among the follicles (<bold>A</bold>, <bold>B</bold>). While follicular structures were positive for thyroglobulin (<bold>C</bold>), thyroperoxidase (<bold>D</bold>), TTF1 (<bold>E</bold>), and PAX8 (<bold>F</bold>), the morular component was negative for thyroglobulin and thyroperoxidase. Only a few isolated cells were found to be positive for TTF1 and PAX8 (<bold>E</bold>, <bold>F</bold>). In contrast to the membranous pattern of the follicular cell component, strong nuclear and cytoplasmic positivity for &#946;-catenin was evident in the morules (<bold>G</bold>, <bold>H</bold>)</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12022_2025_9874_Fig3_HTML.jpg"/></fig></p><p id="Par9">The remainder of the thyroid parenchyma was occupied by well-circumscribed or partially encapsulated nodules of similar appearance, showing a macrofollicular growth pattern, with colloid-filled follicles and frequent short papillary projections (Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). The cells were cuboidal with nuclear characteristics like those of the main encapsulated nodule, including intermediate-type nuclei (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B and D). Cystic changes were detected in one of these nodules (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). No significant mitotic activity, necrosis, infiltration, or angioinvasion was detected. No evidence of thyroiditis was found<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><italic toggle="yes">DICER1</italic>-associated thyroid follicular nodular disease. These two proliferative nodules (<bold>A</bold>, <bold>C</bold>) showed a predominant macrofollicular pattern with some papillary projections. At a higher magnification, nuclear overlapping and clear nuclei could be seen (<bold>B</bold>, <bold>D</bold>)</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="12022_2025_9874_Fig4_HTML.jpg"/></fig></p><p id="Par10">The main results of the immunohistochemical study are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The follicular component of the encapsulated nodule showed positivity for thyroglobulin, thyroperoxidase, TTF1, PAX8, keratin clones CKAE1/AE3, 34bE12, and CK19 (weak), and vimentin, with a Ki67 proliferation index of 21% (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). In contrast, the morular component showed negativity for thyroglobulin, thyroperoxidase, and vimentin, with positivity for TTF1 and PAX8 in isolated cells, diffuse positivity for keratin clones CKAE1/AE3 and CK19, CD10, CDX2, and a Ki67 index of less than 1% (Figs.&#160;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). While the &#946;-catenin staining pattern of the tumor follicular cells was membranous, the morular component showed a strong nuclear, cytoplasmic staining pattern for &#946;-catenin (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>G and H). The other nodules present in the thyroid parenchyma showed positivity for thyroglobulin with negativity for calcitonin.
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>DICER1-related pediatric thyroid neoplasm with follicular and morular growth. Diffuse positivity for CKAE1/AE3 was found both in the follicular and morular components (<bold>A</bold>), but positivity for CD10 (<bold>B</bold>) and CDX2 (<bold>C</bold>) was confined solely to the morular structures. A high Ki67 proliferation index (21%) was restricted to the follicular cell component of the tumor (<bold>D</bold>)</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="12022_2025_9874_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Genetic Features</title><p id="Par11">The results of the mutational study are shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The same <italic toggle="yes">DICER1</italic> (c.4068_4069delGT, p(Tyr1357fs*18) constitutional pathogenic variant was identified in the &#8220;normal&#8221; thyroid tissue (variant allele frequency [VAF]: 51%), the main nodule (VAF: 50%), and the thyroid adenoma (VAF: 52%). In addition to the constitutional <italic toggle="yes">DICER1</italic> c.4068_4069delGT, p.(Tyr1357fs*18) variant, the oncogenic somatic variant <italic toggle="yes">DICER1</italic> c.5428G&#8201;&gt;&#8201;T, p.(Asp1810Tyr) (VAF: 32%) and the oncogenic somatic variant <italic toggle="yes">CTNNB1</italic> c.121A&#8201;&gt;&#8201;G, p.(Thr41Ala) (VAF: 23%) were identified in the main nodule. The additional study of one of the macrofollicular adenomas confirmed the constitutional <italic toggle="yes">DICER1</italic> c.4068_4069delGT, p(Tyr1357fs*18) variant, along with two somatic <italic toggle="yes">DICER1</italic> variants c.5126A&#8201;&gt;&#8201;G, p.(Asp1709Gly) (VAF: 19%) and c.5429A&#8201;&gt;&#8201;T, p.(Asp1810Val) (VAF: 11%). No alterations in the genes <italic toggle="yes">APC</italic>, <italic toggle="yes">AXIN1</italic>, <italic toggle="yes">AXIN2</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">NRAS</italic>, <italic toggle="yes">HRAS</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">EIF1AX</italic>, <italic toggle="yes">PTEN</italic>, <italic toggle="yes">TERT</italic>, <italic toggle="yes">PI3KCA</italic>, <italic toggle="yes">KMT2C</italic>, <italic toggle="yes">KMT2D</italic>, <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">ATM</italic>, and <italic toggle="yes">TP53</italic> were detected in any of the samples from the main nodule, thyroid adenoma, or &#8220;normal&#8221; thyroid. The insufficient quantity and quality of DNA did not allow for specific molecular study of the morular component.
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par12">Until now, the spectrum of thyroid alterations associated with constitutional pathogenic variants in <italic toggle="yes">DICER1</italic> has included TFND, differentiated thyroid carcinoma, sometimes combining high-grade areas (tumor-in-tumor pattern)&#160;and poorly differentiated thyroid carcinoma (PDTC) &#160;[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In <italic toggle="yes">DICER1</italic> syndrome, TFND consists of multiple, bilateral, well-circumscribed nodular proliferations of follicular cells with frequent macrofollicular and/or papillary architecture (so-called papillary hyperplasia or papillary adenoma). Most malignant tumors are well differentiated and have been reported primarily as cases of follicular variant of papillary thyroid carcinoma (PTC) and minimally invasive follicular thyroid carcinoma (FTC) [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Due to the frequent presence of intermediate-type nuclear characteristics in these lesions [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], however, it is not easy to classify these tumors within the <italic toggle="yes">RAS</italic>-like and <italic toggle="yes">BRAF</italic>-like scheme [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Therefore, the designation <italic toggle="yes">DICER1</italic>-associated well-differentiated thyroid carcinoma/tumor has been proposed, depending on whether or not they are accompanied by invasive characteristics, respectively [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. PDTC has also been described in this syndrome using the Turin consensus diagnostic criteria [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, additional histopathological features such as the detection of multiple areas of thick hyaline ischemic-like stroma (atrophic changes), preferably in the subcapsular region of these tumors or outside the nodules [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] as well as the presence of aggregates of ectatic macrofollicles (involutional changes) in the extranodular thyroid [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], may alert the pathologist concerning a somatic and/or germline <italic toggle="yes">DICER1</italic> alteration [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par13">Thyroblastoma is an embryonal high-grade triphasic thyroid neoplasm composed of (1) primitive thyroid epithelium (positive for thyroglobulin, TTF1, and PAX8), (2) a blastemal component of small cells positive for SALL-4, and (3) a spindle cell stroma usually positive for alpha-smooth muscle actin, desmin, and myogenin [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Thyroblastoma, however, is unrelated to the hereditary <italic toggle="yes">DICER1</italic> syndrome, but is associated with somatic mutations in <italic toggle="yes">DICER1</italic> [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par14">In the present case, the thyroid gland showed alterations typically associated with <italic toggle="yes">DICER1</italic> syndrome, including TFND with some nodules showing a predominantly macrofollicular pattern with cystic change and papillary formations in variable proportions. The constitutional <italic toggle="yes">DICER1</italic> mutation was confirmed in histologically normal thyroid tissue, in one of the TNFD nodules and in the main nodule. Other studies have shown different additional somatic mutations of <italic toggle="yes">DICER1</italic> in TFND nodules [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par15">To our knowledge, this manuscript describes, for the first time, a thyroid tumor with a peculiar mixed follicular and morular growth pattern that expands the spectrum of thyroid lesions associated with <italic toggle="yes">DICER1</italic> syndrome. In the present tumor, the follicular component of the tumor showed colloid in the follicular lumen surrounded by cells whose nuclei had some characteristics (clearance and overlapping) insufficient for the diagnosis of PTC. These &#8220;intermediate-type&#8221; nuclear characteristics, following the terminology coined by Sobrinho-Simoes&#8217; group [<xref ref-type="bibr" rid="CR20">20</xref>], are consistent with those previously described in <italic toggle="yes">DICER1</italic>-associated tumors (see above) and reflect the non-<italic toggle="yes">RAS</italic> and non-<italic toggle="yes">BRAF</italic> pathogenesis of these tumors. In addition to the constitutional <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) variant, the somatic <italic toggle="yes">DICER1</italic> p.(Asp1910Tyr) oncogenic variant was also identified in this tumor. The follicular areas of the tumor were positive for thyroglobulin, thyroperoxidase, TTF1, and PAX8, supporting a follicular lineage, while the meaning of the morular structures is intriguing. The morular component, squamoid but not keratinizing, showed positivity for TTF1 and PAX8 in a few isolated peripheral cells, negativity for other follicular lineage markers, and positivity for CD10 and CDX2, as well as intense nuclear and cytoplasmic positivity for &#946;-catenin. Among thyroid tumors, the existence of morulae with a similar immunohistochemical profile has been described in the cribriform morular thyroid carcinoma (CMTC) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], but similar morulae have also been reported in tumors of other organs such as the low-grade fetal adenocarcinomas of the lung [<xref ref-type="bibr" rid="CR29">29</xref>], pancreatoblastoma [<xref ref-type="bibr" rid="CR30">30</xref>], some colorectal adenomas and carcinomas [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and endometrioid-type endometrial and ovarian carcinomas [<xref ref-type="bibr" rid="CR33">33</xref>]. All of these belong to the family of tumors containing CD10-positive morulae and share alterations in the WNT/&#946;&#8208;catenin signaling pathway [<xref ref-type="bibr" rid="CR34">34</xref>]. In addition to the constitutional and somatic <italic toggle="yes">DICER1</italic> oncogenic variants, the somatic <italic toggle="yes">CTNNB1</italic> p.(Thr41Ala) oncogenic variant was also identified in the present tumor, which also justified its histopathogenic relationship with the family of tumors containing CD10-positive morulae.</p><p id="Par16">CMTC is a tumor with a particular histological growth pattern and strong nuclear and cytoplasmic &#946;-catenin staining secondary to constitutive activation of the WNT/&#946;-catenin [<xref ref-type="bibr" rid="CR35">35</xref>]. CMTC is typically associated with familial adenomatous polyposis but can also occur sporadically [<xref ref-type="bibr" rid="CR14">14</xref>]. CMTC exhibits an intricate blending of cribriform, follicular, papillary, trabecular, and solid growth patterns, with morular areas. While the follicular/glandular pattern (and all other patterns) of CMTC lacks colloid and is consistently negative for thyroglobulin and PAX8 [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], the follicular component in this present&#160;case showed colloid and was positive for these markers. The histogenesis of CMTC is uncertain [<xref ref-type="bibr" rid="CR28">28</xref>], and a relationship with the thymic/ultimobranchial pouch has been suggested because of the negativity for follicular markers and the immunoreactivity of morulae for CD5 and keratin 5 [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Our group, in contrast, has suggested a follicular lineage and has attributed the lack of follicular differentiation of CMTC to the activation of the WNT/&#946;-catenin signaling pathway [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par17">WNT/&#946;-catenin signaling is a critical component of intestinal stem cells [<xref ref-type="bibr" rid="CR39">39</xref>], and it is accepted that the activation of WNT/&#946;&#8208;catenin signaling, through transcription factor CDX2, activates colonic gene expression at high levels [<xref ref-type="bibr" rid="CR40">40</xref>]. The fact that all CMTC cells show nuclear/cytoplasmic positivity for &#946;-catenin and negativity for thyroglobulin, while the thyroglobulin expression in&#160;the present neoplasm is limited to the tumor cells with nuclear/cytoplasmic negativity for &#946;-catenin and vice versa, fits in well with our proposal of a follicular origin for CMTC. While in familial or sporadic CMTC, the permanent activation of the WNT/&#946;-catenin pathway has been explained by alterations in the different components of this pathway [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]; in the present tumor , the restriction of the WNT/&#946;-catenin pathway activation (and nuclear/cytoplasmic positivity for &#946;-catenin) to the morular component distributed throughout the tumor is puzzling. Concurrent with the germline and somatic mutations of <italic toggle="yes">DICER1</italic>, a pathogenic mutation in the <italic toggle="yes">CTNNB1</italic> gene was also confirmed in our present tumor, which would explain the activation of the WNT/&#946;-catenin in the morular structures. Unfortunately, we were unable to obtain sufficient quality DNA from the morulae for a specific molecular analysis. This is a limitation since a more in-depth molecular study of morulae could lead to a better understanding of phenotypic/genetic relationships, particularly in the context of WNT/&#946;-catenin-induced differentiation in DICER1-associated thyroid tumors.</p><p id="Par18">Most low-grade fetal adenocarcinoma/well-differentiated fetal adenocarcinoma (WDFA) of the lung shows nuclear expression of &#946;-catenin and <italic toggle="yes">CTNNB1</italic> somatic mutations [<xref ref-type="bibr" rid="CR29">29</xref>], but the coexistence of mutations in <italic toggle="yes">CTNNB1</italic> and <italic toggle="yes">DICER1</italic> is uncommon [<xref ref-type="bibr" rid="CR29">29</xref>]. Analogous to what occurred in this present tumor, however, a case of WDFA of the lung with coexistence of <italic toggle="yes">CTNNB1</italic> and <italic toggle="yes">DICER1</italic> mutations in a 16-year-old girl with a history of TFND, ovarian Sertoli-Leydig cell tumor, and familial <italic toggle="yes">DICER1</italic> syndrome has been described [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par19">This DICER1-related pediatric thyroid neoplasm with follicular and morular growth lacks the malignant features typically associated with malignant follicular cell thyroid neoplasms; this tumor is an encapsulated neoplasm with no evidence of invasiveness. Neither is there any evidence of necrosis, and the nuclear atypia is insufficient for a diagnosis of PTC. The presence of mitotic figures and the high Ki67 index in this case appear to reflect the state of the developing young thyroid gland more than the aggressiveness of the tumor [<xref ref-type="bibr" rid="CR42">42</xref>]. The Ki67 index alone does not appear to impact the prognosis of pediatric thyroid tumors [<xref ref-type="bibr" rid="CR43">43</xref>], including noninvasive thyroid tumors associated with <italic toggle="yes">DICER1</italic> [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. For this reason, and in relation to the diagnosis of PDTC, some authors have questioned the use of the Turin consensus criteria in the pediatric population [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Finally, although there is no evidence of malignancy, as it is a single tumor, it is not possible to conclusively establish the prognosis of the present tumor.</p><p id="Par20">In conclusion, here, we describe, for the first time, an encapsulated follicular cell thyroid tumor showing a mixed follicular and morular growth pattern, which presented in an 11-year-old girl with follicular nodular disease and a constitutional <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) pathogenic variant. The follicular areas were positive for thyroglobulin, while the morular component was positive for CD10 and CDX2. Aberrant (nuclear and cytoplasmic) immunolabeling pattern for &#946;-catenin was limited to the morular structures. In addition to the constitutional <italic toggle="yes">DICER1</italic> p.(Tyr1357fs*18) variant, the somatic <italic toggle="yes">DICER1</italic> p.(Asp1910Tyr) oncogenic variant and the somatic <italic toggle="yes">CTNNB1</italic> p.(Thr41Ala) oncogenic variant were also identified. This peculiar tumor expands the spectrum of <italic toggle="yes">DICER1</italic>-associated thyroid lesions and indirectly establishes a pathogenetic relationship with CMTC.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>We wish to thank the patient and her parents for their kind generosity which will help to improve the diagnosis and treatment of thyroid tumors. The authors apologize to the investigators whose original work was not cited owing to space constrains.</p></ack><notes notes-type="author-contribution"><title>Author Contribution
</title><p>Conception, design and figures: JMC-T and MS-S; Data collection and analysis: all authors; Manuscript preparation and editing: JMC-T, SV and MS-S; Approval of final manuscript: all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported (JMC-T) by Instituto de Salud Carlos III (ISCIII), Spain, grant PI23/00722, co-funded by the European Union.</p></notes><notes notes-type="data-availability"><title>Data Availability
</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics Approval and Consent to Participate</title><p id="Par21">Retrospective study. Written informed consent was obtained from the parents.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1. </label><mixed-citation publication-type="other">de Kock L, Gill AJ, Mete O, Foulkes WD, Nos&#233; V. DICER1 syndrome. In: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2025. (WHO classification of tumours series, 5th ed.; vol. 10). <ext-link ext-link-type="uri" xlink:href="https://publications.iarc.who.int/645">https://publications.iarc.who.int/645</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2. </label><mixed-citation publication-type="other">Anglesio MS, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, Salamanca C, Maines-Bandiera S, Huntsman DG, Morin GB. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol. 2013;229(3):400-9. 10.1002/path.4135. PMID: 23132766.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4135</pub-id><pub-id pub-id-type="pmid">23132766</pub-id></mixed-citation></ref><ref id="CR3"><label>3. </label><mixed-citation publication-type="other">Ricarte-Filho JC, Casado-Medrano V, Reichenberger E, Spangler Z, Scheerer M, Isaza A, Baran J, Patel T, MacFarland SP, Brodeur GM, Stewart DR, Baloch Z, Bauer AJ, Wasserman JD, Franco AT. DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer. Front Endocrinol (Lausanne). 2023;14:1083382. 10.3389/fendo.2023.1083382. PMID: 36896180; PMCID: PMC9990750.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1083382</pub-id><pub-id pub-id-type="pmcid">PMC9990750</pub-id><pub-id pub-id-type="pmid">36896180</pub-id></mixed-citation></ref><ref id="CR4"><label>4. </label><mixed-citation publication-type="other">Capozzi A, Jansen FA, Smetsers SE, Bakhuizen JJ, Hiemcke-Jiwa LS, Kranendonk MEG, Flucke U, Alaggio R, de Krijger RR. The Histological Spectrum of DICER1-Associated Neoplasms. Pediatr Dev Pathol. 2025:10935266251329752. 10.1177/10935266251329752. PMID: 40231379.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10935266251329752</pub-id><pub-id pub-id-type="pmid">40231379</pub-id></mixed-citation></ref><ref id="CR5"><label>5. </label><mixed-citation publication-type="other">Cameselle-Teijeiro JM, Erickson LA, LiVolsi V, Nos&#233; V. Syndromic familial follicular cell-derived thyroid tumours. In: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2025. (WHO classification of tumours series, 5th ed.; vol. 10). <ext-link ext-link-type="uri" xlink:href="https://publications.iarc.who.int/645">https://publications.iarc.who.int/645</ext-link>.
</mixed-citation></ref><ref id="CR6"><label>6. </label><mixed-citation publication-type="other">Chernock RD, Rivera B, Borrelli N, Hill DA, Fahiminiya S, Shah T, Chong AS, Aqil B, Mehrad M, Giordano TJ, Sheridan R, Rutter MM, Dehner LP, Foulkes WD, Nikiforov YE. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Mod Pathol. 2020;33(7):1264-1274. 10.1038/s41379-020-0458-7. PMID: 31937902; PMCID: PMC7329587.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41379-020-0458-7</pub-id><pub-id pub-id-type="pmcid">PMC7329587</pub-id><pub-id pub-id-type="pmid">31937902</pub-id></mixed-citation></ref><ref id="CR7"><label>7. </label><mixed-citation publication-type="other">Yegen G, Altay AY, Y&#305;lmaz &#304;, &#304;&#351;can Y, Sormaz &#304;C, Aksakal N, &#214;nder S, Mete &#214;. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas. Endocr Pathol. 2023;34(3):279-286. 10.1007/s12022-023-09780-2. PMID: 37574466.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-023-09780-2</pub-id><pub-id pub-id-type="pmid">37574466</pub-id></mixed-citation></ref><ref id="CR8"><label>8. </label><mixed-citation publication-type="other">Agaimy A, Witkowski L, Stoehr R, Cuenca JCC, Gonz&#225;lez-Muller CA, Br&#252;tting A, B&#228;hrle M, Mantsopoulos K, Amin RMS, Hartmann A, Metzler M, Amr SS, Foulkes WD, Sobrinho-Sim&#245;es M, Eloy C. Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations-is the term "thyroblastoma" more appropriate? Virchows Arch. 2020;477(6):787-798. 10.1007/s00428-020-02853-1. PMID: 32507920; PMCID: PMC7683491.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-020-02853-1</pub-id><pub-id pub-id-type="pmcid">PMC7683491</pub-id><pub-id pub-id-type="pmid">32507920</pub-id></mixed-citation></ref><ref id="CR9"><label>9. </label><mixed-citation publication-type="other">Cameselle-Teijeiro JM, Mete O, Asa SL, LiVolsi V. Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocr Pathol. 2021;32(1):77-101. 10.1007/s12022-020-09661-y. PMID: 33495912; PMCID: PMC7960606.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-020-09661-y</pub-id><pub-id pub-id-type="pmcid">PMC7960606</pub-id><pub-id pub-id-type="pmid">33495912</pub-id></mixed-citation></ref><ref id="CR10"><label>10. </label><mixed-citation publication-type="other">Condello V, Roberts JW, Stenman A, Larsson C, Viswanathan K, Juhlin CC. Atrophic changes in thyroid tumors are strong indicators of underlying DICER1 mutations: a bi-institutional genotype-phenotype correlation study. Virchows Arch. 2024;485(1):105-114. 10.1007/s00428-024-03802-y. PMID: 38637342; PMCID: PMC11271315.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-024-03802-y</pub-id><pub-id pub-id-type="pmcid">PMC11271315</pub-id><pub-id pub-id-type="pmid">38637342</pub-id></mixed-citation></ref><ref id="CR11"><label>11. </label><mixed-citation publication-type="other">Jung CK, Liu Z, Hirokawa M, Bychkov A. Histological clues of DICER1 mutations in thyroid nodules. Virchows Arch. 2024;485(4):755-757. 10.1007/s00428-024-03915-4. PMID: 39231821.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-024-03915-4</pub-id><pub-id pub-id-type="pmid">39231821</pub-id></mixed-citation></ref><ref id="CR12"><label>12. </label><mixed-citation publication-type="other">Schiavo Lena M, S&#225;nchez-Ares M, Brunetto E, Abdulkader-Nallib I, Maggiore R, Barbieri D, Vigone MC, Perticone F, Lanzi R, Presi S, Carrera P, Cangi MG, Arrigoni G, Doglioni C, Cameselle-Teijeiro JM. Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma? Endocr Pathol. 2025 May 31;36(1):20. 10.1007/s12022-025-09863-2. PMID: 40448797.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-025-09863-2</pub-id><pub-id pub-id-type="pmcid">PMC12126348</pub-id><pub-id pub-id-type="pmid">40448797</pub-id></mixed-citation></ref><ref id="CR13"><label>13. </label><mixed-citation publication-type="other">Juhlin CC, Mete O. Letter to the Editor: Morphological Indicators of DICER1 Mutations May Guide Somatic and Germline Testing. Thyroid. 2025;35(1):120-121. 10.1089/thy.2024.0556. PMID: 39714925.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2024.0556</pub-id><pub-id pub-id-type="pmid">39714925</pub-id></mixed-citation></ref><ref id="CR14"><label>14. </label><mixed-citation publication-type="other">Cameselle-Garc&#237;a S, Abdulkader-Nallib I, S&#225;nchez-Ares M, Cameselle-Teijeiro JM. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review). Oncol Rep. 2024;52(3):119. 10.3892/or.2024.8778. PMID: 39027989; PMCID: PMC11292300.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2024.8778</pub-id><pub-id pub-id-type="pmcid">PMC11292300</pub-id><pub-id pub-id-type="pmid">39027989</pub-id></mixed-citation></ref><ref id="CR15"><label>15. </label><mixed-citation publication-type="other">Garrido-Gil P, Fernandez-Rodr&#237;guez P, Rodr&#237;guez-Pallares J, Labandeira-Garcia JL. Laser capture microdissection protocol for gene expression analysis in the brain. Histochem Cell Biol.;148(3):299&#8211;311. 10.1007/s00418-017-1585-1. PMID: 28560490.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00418-017-1585-1</pub-id><pub-id pub-id-type="pmid">28560490</pub-id></mixed-citation></ref><ref id="CR16"><label>16. </label><mixed-citation publication-type="other">Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24(5):986-998. 10.1016/j.gim.2022.01.001. Erratum in: Genet Med. 2022;24(9):1991. 10.1016/j.gim.2022.07.001. PMID: 35101336; PMCID: PMC9081216.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gim.2022.01.001</pub-id><pub-id pub-id-type="pmcid">PMC9081216</pub-id><pub-id pub-id-type="pmid">35101336</pub-id></mixed-citation></ref><ref id="CR17"><label>17. </label><mixed-citation publication-type="other">Nos&#233; V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocr Pathol. 2022;33(1):197-227. 10.1007/s12022-022-09705-5. PMID: 35285003.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-022-09705-5</pub-id><pub-id pub-id-type="pmid">35285003</pub-id></mixed-citation></ref><ref id="CR18"><label>18. </label><mixed-citation publication-type="other">Onder S, Mete O, Yilmaz I, Bayram A, Bagbudar S, Altay AY, Issin G, Terzi NK, Iscan Y, Sormaz IC, Tunca F, Senyurek YG, Yegen G. DICER1 Mutations Occur in More Than One-Third of Follicular-Patterned Pediatric Papillary Thyroid Carcinomas and Correlate with a Low-Risk Disease and Female Gender Predilection. Endocr Pathol. 2022;33(4):437-445. 10.1007/s12022-022-09736-y. PMID: 36251117.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-022-09736-y</pub-id><pub-id pub-id-type="pmid">36251117</pub-id></mixed-citation></ref><ref id="CR19"><label>19. </label><mixed-citation publication-type="other">Mastnikova K, Bulanova Pekova B, Kuklikova V, Vaclavikova E, Carkova J, Katra R, Fialova L, Vlcek P, Kodetova D, Chovanec M, Drozenova J, Matej R, Pacesova P, Novak Z, Procykova K, Vcelak J, Bendlova B. DICER1 Variants in Pediatric and Young Adult Thyroid Nodules. Thyroid. 2024 Oct;34(10):1225-1233. 10.1089/thy.2024.0188. Epub 2024 Sep 27. PMID: 39283830.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2024.0188</pub-id><pub-id pub-id-type="pmid">39283830</pub-id></mixed-citation></ref><ref id="CR20"><label>20. </label><mixed-citation publication-type="other">Gullo I, Batista R, Rodrigues-Pereira P, Soares P, Barroca H, do Bom-Sucesso M, Sobrinho-Sim&#245;es M. Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations. Am J Clin Pathol. 2018;149(5):379&#8211;386. 10.1093/ajcp/aqy004. PMID: 29538609.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcp/aqy004</pub-id><pub-id pub-id-type="pmid">29538609</pub-id></mixed-citation></ref><ref id="CR21"><label>21. </label><mixed-citation publication-type="other">Shin SH, Yoon JH, Son MH, Kim SJ, Park SY, Kim HY, Lee HS, Park HJ, Park BK. Follicular thyroid carcinoma arising after hematopoietic stem cell transplantation in a child with pleuropulmonary blastoma. Thyroid. 2012 May;22(5):547-51. 10.1089/thy.2011.0161. Epub 2012 Apr 2. PMID: 22468940.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2011.0161</pub-id><pub-id pub-id-type="pmid">22468940</pub-id></mixed-citation></ref><ref id="CR22"><label>22. </label><mixed-citation publication-type="other">Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, Wu MK, Shlien A, de Kock L, Foulkes WD. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 May 1;103(5):2009-2015. 10.1210/jc.2017-02698. Erratum in: J Clin Endocrinol Metab. 2018 Aug 1;103(8):3114. 10.1210/jc.2018-01190. PMID: 29474644.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2017-02698</pub-id><pub-id pub-id-type="pmid">29474644</pub-id></mixed-citation></ref><ref id="CR23"><label>23. </label><mixed-citation publication-type="other">Lengyel K, Lubin DJ, Hsiao WY, Sirotnikov S, Luo G, Roberts JW, Shi Q, Magliocca K, Lewis MM, Sears DL, Ilyas G, Rogers BB, Viswanathan K. Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1-altered thyroid lesions on FNA: A multipractice experience. Cancer Cytopathol. 2024 Jun;132(6):359-369. 10.1002/cncy.22805. Epub 2024 Mar 23. PMID: 38520219.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncy.22805</pub-id><pub-id pub-id-type="pmid">38520219</pub-id></mixed-citation></ref><ref id="CR24"><label>24. </label><mixed-citation publication-type="other">Whaley RD, Gupta S, Manninen MC, O'Brien DR, Erickson LA. Clinicopathologic and Molecular Analysis of 15 Pediatric and Young Adult Patients with High-Grade Non-anaplastic Thyroid Carcinoma. Endocr Pathol. 2024;35(4):397-410. 10.1007/s12022-024-09842-z. PMID: 39636536.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-024-09842-z</pub-id><pub-id pub-id-type="pmid">39636536</pub-id></mixed-citation></ref><ref id="CR25"><label>25. </label><mixed-citation publication-type="other">Juhlin CC, Stenman A, Zedenius J. Macrofollicular variant follicular thyroid tumors are DICER1 mutated and exhibit distinct histological features. Histopathology. 2021;79(4):661-666. 10.1111/his.14416. PMID: 34008223.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.14416</pub-id><pub-id pub-id-type="pmid">34008223</pub-id></mixed-citation></ref><ref id="CR26"><label>26. </label><mixed-citation publication-type="other">Agaimy A, Nos&#233; V, Sobrinho-Sim&#245;es M. Thyroblastoma. In: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2025. (WHO classification of tumours series, 5th ed.; vol. 10). <ext-link ext-link-type="uri" xlink:href="https://publications.iarc.who.int/645">https://publications.iarc.who.int/645</ext-link>.
</mixed-citation></ref><ref id="CR27"><label>27. </label><mixed-citation publication-type="other">de Kock L, Bah I, Revil T, B&#233;rub&#233; P, Wu MK, Sabbaghian N, Priest JR, Ragoussis J, Foulkes WD. Deep Sequencing Reveals Spatially Distributed Distinct Hot Spot Mutations in DICER1-Related Multinodular Goiter. J Clin Endocrinol Metab. 2016 Oct;101(10):3637-3645. 10.1210/jc.2016-1328. Epub 2016 Jul 26. PMID: 27459524.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2016-1328</pub-id><pub-id pub-id-type="pmid">27459524</pub-id></mixed-citation></ref><ref id="CR28"><label>28. </label><mixed-citation publication-type="other">Erickson LA, Mete O, Cameselle-Teijeiro JM, LiVolsi V, Nos&#233; V, Sobrinho-Sim&#245;es M, Jung CK. Cribriform-morular thyroid carcinoma. In: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2025. (WHO classification of tumours series, 5th ed.; vol. 10). <ext-link ext-link-type="uri" xlink:href="https://publications.iarc.who.int/645">https://publications.iarc.who.int/645</ext-link>.
</mixed-citation></ref><ref id="CR29"><label>29. </label><mixed-citation publication-type="other">Yanagawa N, Uesugi N, Nishiya M, Sugimoto R, Osakabe M, Saitoh H, Maemondo M, Sugai T. Morphological and Molecular Characteristics in Low Grade Fetal Adenocarcinoma of the Lung: Two Case Reports and Literature Review. Int J Surg Pathol. 2022;30(7):797-803. 10.1177/10668969221081741. PMID: 35188818.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10668969221081741</pub-id><pub-id pub-id-type="pmid">35188818</pub-id></mixed-citation></ref><ref id="CR30"><label>30. </label><mixed-citation publication-type="other">Tanaka Y, Kato K, Notohara K, Nakatani Y, Miyake T, Ijiri R, Nishimata S, Ishida Y, Kigasawa H, Ohama Y, Tsukayama C, Kobayashi Y, Horie H. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. J Pathol. 2003;199(2):185-90. 10.1002/path.1262. PMID: 12533831.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.1262</pub-id><pub-id pub-id-type="pmid">12533831</pub-id></mixed-citation></ref><ref id="CR31"><label>31. </label><mixed-citation publication-type="other">Sarlin JG, Mori K. Morules in epithelial tumors of the colon and rectum. Am J Surg Pathol. 1984;8(4):281-5. 10.1097/00000478-198404000-00005. PMID: 6711738.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000478-198404000-00005</pub-id><pub-id pub-id-type="pmid">6711738</pub-id></mixed-citation></ref><ref id="CR32"><label>32. </label><mixed-citation publication-type="other">Mochizuki K, Kondo T, Oishi N, Tahara I, Inoue T, Kasai K, Nakazawa T, Katoh R. Squamous morula formation in colorectal adenoma: Immunohistochemical and molecular analyses. Pathol Res Pract. 2015;211(10):797-800. 10.1016/j.prp.2015.05.002. PMID: 26298635.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2015.05.002</pub-id><pub-id pub-id-type="pmid">26298635</pub-id></mixed-citation></ref><ref id="CR33"><label>33. </label><mixed-citation publication-type="other">Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology. 2008;53(2):156-65. 10.1111/j.1365-2559.2008.03083.x. PMID: 18752499.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2559.2008.03083.x</pub-id><pub-id pub-id-type="pmid">18752499</pub-id></mixed-citation></ref><ref id="CR34"><label>34. </label><mixed-citation publication-type="other">Cameselle-Teijeiro J, Alberte-Lista L, Chiarelli S, Buritic&#225; C, Gon&#231;alves L, Gonz&#225;lez-C&#225;mpora R, Nogales FF. CD10 is a characteristic marker of tumours forming morules with biotin-rich, optically clear nuclei that occur in different organs. Histopathology. 2008;52(3):389-92. 10.1111/j.1365-2559.2007.02911.x. PMID: 18081818.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2559.2007.02911.x</pub-id><pub-id pub-id-type="pmid">18081818</pub-id></mixed-citation></ref><ref id="CR35"><label>35. </label><mixed-citation publication-type="other">Cameselle-Teijeiro JM, Peteiro-Gonz&#225;lez D, Caneiro-G&#243;mez J, S&#225;nchez-Ares M, Abdulkader I, Eloy C, Melo M, Amendoeira I, Soares P, Sobrinho-Sim&#245;es M. Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/&#946;-catenin pathway. Mod Pathol. 2018;31(8):1168-1179. 10.1038/s41379-018-0070-2. PMID: 29785019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41379-018-0070-2</pub-id><pub-id pub-id-type="pmid">29785019</pub-id></mixed-citation></ref><ref id="CR36"><label>36. </label><mixed-citation publication-type="other">Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nos&#233; V, Mete O. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol. 2021;32(3):327-335. 10.1007/s12022-021-09683-0. PMID: 34019236; PMCID: PMC9353615.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-021-09683-0</pub-id><pub-id pub-id-type="pmcid">PMC9353615</pub-id><pub-id pub-id-type="pmid">34019236</pub-id></mixed-citation></ref><ref id="CR37"><label>37. </label><mixed-citation publication-type="other">Dettmer MS, H&#252;rlimann S, Scheuble L, Vassella E, Perren A, Wicke C. Cribriform Morular Thyroid Carcinoma - Ultimobranchial Pouch-Related? Deep Molecular Insights of a Unique Case. Endocr Pathol. 2023 Sep;34(3):342-348. 10.1007/s12022-023-09775-z. PMID: 37249797; PMCID: PMC10511600.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-023-09775-z</pub-id><pub-id pub-id-type="pmcid">PMC10511600</pub-id><pub-id pub-id-type="pmid">37249797</pub-id></mixed-citation></ref><ref id="CR38"><label>38. </label><mixed-citation publication-type="other">Echegoyen-Silanes A, Pineda-Arribas JJ, S&#225;nchez-Ares M, Cameselle-Garc&#237;a S, Sobrino B, Ru&#237;z-Ponte C, Piso-Neira M, Anda E, Cameselle-Teijeiro JM. Cribriform morular thyroid carcinoma: a case report with pathological, immunohistochemical, and molecular findings suggesting an origin from follicular cells (or their endodermal precursors). Virchows Arch. 2023 Mar;482(3):615&#8211;623. 10.1007/s00428-023-03495-9. Epub 2023 Jan 23. PMID: 36689061; PMCID: PMC10033468.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-023-03495-9</pub-id><pub-id pub-id-type="pmcid">PMC10033468</pub-id><pub-id pub-id-type="pmid">36689061</pub-id></mixed-citation></ref><ref id="CR39"><label>39. </label><mixed-citation publication-type="other">Faizo NL. The intestinal stem cell as a target: A review. Medicine (Baltimore). 2024;103(34):e39456. 10.1097/MD.0000000000039456. PMID: 39183418; PMCID: PMC11346866.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000039456</pub-id><pub-id pub-id-type="pmcid">PMC11346866</pub-id><pub-id pub-id-type="pmid">39183418</pub-id></mixed-citation></ref><ref id="CR40"><label>40. </label><mixed-citation publication-type="other">Sherwood RI, Maehr R, Mazzoni EO, Melton DA. Wnt signaling specifies and patterns intestinal endoderm. Mech Dev. 2011;128(7-10):387-400. 10.1016/j.mod.2011.07.005. PMID: 21854845; PMCID: PMC3223331.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mod.2011.07.005</pub-id><pub-id pub-id-type="pmcid">PMC3223331</pub-id><pub-id pub-id-type="pmid">21854845</pub-id></mixed-citation></ref><ref id="CR41"><label>41. </label><mixed-citation publication-type="other">de Kock L, Bah I, Wu Y, Xie M, Priest JR, Foulkes WD. Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung. J Thorac Oncol. 2016;11(3):e31-3. 10.1016/j.jtho.2015.09.012. PMID: 26886166.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2015.09.012</pub-id><pub-id pub-id-type="pmid">26886166</pub-id></mixed-citation></ref><ref id="CR42"><label>42. </label><mixed-citation publication-type="other">Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, Bove KE, Nikiforov YE. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab. 2006 Jul;91(7):2672-7. 10.1210/jc.2006-0417. Epub 2006 May 2. PMID: 16670159.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2006-0417</pub-id><pub-id pub-id-type="pmid">16670159</pub-id></mixed-citation></ref><ref id="CR43"><label>43. </label><mixed-citation publication-type="other">Saliba M, Alzumaili BA, Katabi N, Dogan S, Tuttle RM, Zoltan A, Pandit-Taskar N, Xu B, Ghossein RA. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients. Am J Surg Pathol. 2022 Dec 1;46(12):1659&#8211;1669. 10.1097/PAS.0000000000001958. Epub 2022 Aug 29. PMID: 36040037; PMCID: PMC9669120.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000001958</pub-id><pub-id pub-id-type="pmcid">PMC9669120</pub-id><pub-id pub-id-type="pmid">36040037</pub-id></mixed-citation></ref><ref id="CR44"><label>44. </label><mixed-citation publication-type="other">Ver Berne J, Van den Bruel A, Vermeire S, De Paepe P. DICER1 Mutations Define the Landscape of Poorly Differentiated Thyroid Carcinoma in Children and Young Adults: Case Report and Literature Review. Am J Surg Pathol. 2024 Oct 1;48(10):1277-1283. 10.1097/PAS.0000000000002265. Epub 2024 Jun 24. PMID: 38912716.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000002265</pub-id><pub-id pub-id-type="pmid">38912716</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>